Table 2.
Comparison of values of clinical parameters at baseline and at week 12 in the DORZOX treatment group
| Variable (n=38) | Baseline (Day 1) | After 12 weeks of treatment with DORZOX | Difference n (%) | P |
|---|---|---|---|---|
| OPP | 46.63 | 48.71 | 2.06 (4.45) | 0.000587* |
| IOP | 16.05 | 14.53 | −1.53 (−9.51) | 0.007236* |
| OA | ||||
| PSV | 29.81 | 31.78 | 1.97 (6.59) | 0.051379 |
| EDV | 5.21 | 6.44 | 1.23 (23.50) | 0.000291* |
| RI | 0.78 | 0.76 | −0.02 (−2.91) | 0.129192 |
| CRA | ||||
| PSV | 13.07 | 12.09 | −0.97 (−7.44) | 0.094296 |
| EDV | 3.02 | 3.60 | 0.59 (19.40) | 0.044408* |
| RI | 0.74 | 0.68 | −0.06 (−7.92) | 0.051113 |
| SPCA | ||||
| PSV | 12.75 | 14.23 | 1.48 (11.63) | 0.115915 |
| EDV | 3.13 | 4.41 | 1.28 (40.97) | 0.00755* |
| RI | 0.70 | 0.69 | –0.01 (–1.06) | 0.395842 |
CRA=central retinal artery, EDV=end diastolic velocity, IOP=intraocular pressure, OA=ophthalmic artery, OPP=ocular perfusion pressure, PSV=peak systolic velocity, RI=resistive index, SPCA=short posterior ciliary artery. *Denotes that there was significant difference in the ocular perfusion pressure between the healthy subjects and the glaucoma patients